Compare SLNH & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | EQ |
|---|---|---|
| Founded | 1961 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.6M | 157.4M |
| IPO Year | 2005 | 2018 |
| Metric | SLNH | EQ |
|---|---|---|
| Price | $1.15 | $2.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 9.4M | 504.8K |
| Earning Date | 05-15-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,021,000.00 | ★ $41,095,000.00 |
| Revenue This Year | $55.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 80.49 | N/A |
| 52 Week Low | $0.43 | $0.76 |
| 52 Week High | $5.14 | $3.54 |
| Indicator | SLNH | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 45.38 |
| Support Level | $1.07 | $1.68 |
| Resistance Level | $1.41 | $2.61 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 21.43 | 50.00 |
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.